Literature DB >> 23318562

Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients.

Teruhiko Imamura1, Koichiro Kinugawa, Shun Minatsuki, Hironori Muraoka, Naoko Kato, Toshiro Inaba, Hisataka Maki, Taro Shiga, Masaru Hatano, Atsushi Yao, Shunei Kyo, Issei Komuro.   

Abstract

BACKGROUND: Urine osmolality (U-OSM) is valuable to predict response to tolvaptan (TLV) in decompensated heart failure patients, but measurement of U-OSM is not always available on site. METHODS AND
RESULTS: Data were collected from 66 hospitalized patients with decompensated heart failure who had received TLV at 3.75-15 mg/day. U-OSM, which was estimated using the following formula: 1.07×{2×[(urine sodium (mEq/L)]+[urine urea nitrogen (mg/dl)]/2.8+[urine creatinine (mg/dl)]×2/3}+16, was well correlated with the actual measurement (r=0.938, P<0.001). Criteria consisting of C1 (estimated baseline U-OSM>358 mOsm/L) and C2 (%decrease in estimated U-OSM>24% at 4-6 h after the first TLV dose) significantly discriminated responders from non-responders (P<0.05).
CONCLUSIONS: Response to TLV can be predicted using U-OSM, which can be estimated using urine urea nitrogen, sodium, and creatinine concentration data.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318562     DOI: 10.1253/circj.cj-12-1328

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  8 in total

1.  Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.

Authors:  W-L Huang; Y Yang; J Yang; J Yang; H-B Wang; X-L Xiong; Y-F Zhang
Journal:  Herz       Date:  2017-05-18       Impact factor: 1.443

2.  Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials.

Authors:  Chao-Jun Yang; Jun Yang; Jian Yang; Zhi-Xing Fan
Journal:  Int J Clin Exp Med       Date:  2015-12-15

3.  Effects of Sodium Reduction on Energy, Metabolism, Weight, Thirst, and Urine Volume: Results From the DASH (Dietary Approaches to Stop Hypertension)-Sodium Trial.

Authors:  Stephen P Juraschek; Edgar R Miller; Alexander R Chang; Cheryl A M Anderson; John E Hall; Lawrence J Appel
Journal:  Hypertension       Date:  2020-01-20       Impact factor: 10.190

4.  Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.

Authors:  Atsushi Goto; Shuji Terai; Munetaka Nakamura; Masaharu Matsumoto; Isao Sakaida
Journal:  Clin J Gastroenterol       Date:  2014-12-05

Review 5.  Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.

Authors:  Teruhiko Imamura; Koichiro Kinugawa
Journal:  Int J Mol Sci       Date:  2016-01-14       Impact factor: 5.923

6.  Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.

Authors:  Mari Katsumata; Nobuhito Hirawa; Koichiro Sumida; Minako Kagimoto; Yosuke Ehara; Yuki Okuyama; Megumi Fujita; Akira Fujiwara; Mayumi Kobayashi; Yusuke Kobayashi; Yuichiro Yamamoto; Sanae Saka; Keisuke Yatsu; Tetsuya Fujikawa; Yoshiyuki Toya; Gen Yasuda; Kouichi Tamura; Satoshi Umemura
Journal:  Clin Exp Nephrol       Date:  2017-02-11       Impact factor: 2.801

7.  First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery.

Authors:  Anne Kerling; Okan Toka; André Rüffer; Hanna Müller; Sheeraz Habash; Christel Weiss; Sven Dittrich; Julia Moosmann
Journal:  BMC Pediatr       Date:  2019-02-12       Impact factor: 2.125

8.  Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.

Authors:  Shuntaro Ikeda; Kiyotaka Ohshima; Shigehiro Miyazaki; Hisaki Kadota; Hideaki Shimizu; Akiyoshi Ogimoto; Mareomi Hamada
Journal:  ESC Heart Fail       Date:  2017-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.